Simultaneous Determination of Metronidazole and Diiodohydroxyquine in Bulk Powder and Paramibe Compound Tablets by TLC-Densitometry and HPLC

Metronidazole (MTR), is 2-(2-methyl-5-nitro-1H-imidazol-1yl) ethanol (Figure 1a). It is used as antibacterial and antiamaebiasis [1]. Metronidazole is metabolized by oxidation to 2–hydroxymethyl metronidazole and 2–methyl–5–nitroimidazol–1–acetic acid, and by conjugation with glucuronic acid. About 70 to 80% of a dose is excreted in the urine in 48 hr with less than 10% of the dose as unchanged drug, up to 10% as conjugated MTR, about 27% as 2– hydroxymethylmetronidazole, 10% as the conjugated 2–hydroxymethyl metabolite, and 20% as the acid metabolite [2]. Diiodohydroxyquinoline (DIQ), 5,7-diiodoquinolin-8-ol (Figure 1b). It is widely known by the trade name Diodoquin, is a quinoline derivative which can be used in the treatment of amoebiasis. Iodoquinol is poorly absorbed from the gastrointestinal tract and is amebicidal at the site of infection. It acts by chelating ferrous ions essential for metabolism [3].


Introduction
Metronidazole (MTR), is 2-(2-methyl-5-nitro-1H-imidazol-1yl) ethanol ( Figure 1a). It is used as antibacterial and antiamaebiasis [1]. Metronidazole is metabolized by oxidation to 2-hydroxymethyl metronidazole and 2-methyl-5-nitroimidazol-1-acetic acid, and by conjugation with glucuronic acid. About 70 to 80% of a dose is excreted in the urine in 48 hr with less than 10% of the dose as unchanged drug, up to 10% as conjugated MTR, about 27% as 2hydroxymethylmetronidazole, 10% as the conjugated 2-hydroxymethyl metabolite, and 20% as the acid metabolite [2]. Diiodohydroxyquinoline (DIQ), 5,7-diiodoquinolin-8-ol (Figure 1b). It is widely known by the trade name Diodoquin, is a quinoline derivative which can be used in the treatment of amoebiasis. Iodoquinol is poorly absorbed from the gastrointestinal tract and is amebicidal at the site of infection. It acts by chelating ferrous ions essential for metabolism [3].
The literature survey reveals several analytical methods for quantitative estimation of MTR in body fluids and in pharmaceutical formulations these methods include ultaviolet spectrophotometry [4][5][6], high-performance liquid formulations (HPLC) [7,8] and voltammetry [9]. Quantitation of metronidazole and spiramycin in human plasma, saliva and gingival crevicular fluid by LC-MS/MS [10]. Simultaneous multi residue determination of metronidazole and spiramycin in fish muscle using high performance liquid chromatography with UV detection [11]. Microsized Graphite Sensors for potentiometric determination of metronidazole and spiramycin [12]. DIQ was determined in pharmaceutical formulations using HPLC [13].
The present work aimed to develop simple instrumental methods for simultaneous determination of MTR and DIQ in combination. These methods include as chromatographic methods; namely, TLCdensitometry method and HPLC [14].   linomat autosampler (Switzerland), Camag microsyringe (100 µL). A liquid chromatography consisted of an quaternary pump (Agilent Model G1316A/G1316B), a diode array multiple wavelength detector (Model G1316 C/D and G1365C/D, Agilent 1200 Series), standard and preparation autosamplers (Agilent 1200 series) equipped vacuum degasser, Agilent. Stationary phase (250 mm×4.6 mm, 10 µm) C 18 Lichrosorb TM 10 µm analytical column, Alltech (USA). Mobile phase; methanol and acetonitrile (96:4, v/v) isocratically at 0.6 mL min −1 . The mobile phase was filtered through a 0.45 µm millipore membrane filter and was degassed for ~15 min in an ultrasonic bath prior to use. UVdetection was done at 254 nm. The samples were filtered also through a 0.45 µm membrane filter.

Standard solutions
MTR standard solution and DIQ standard solution (0.5 mg mL −1 each) in mobile phase for the HPLC method and MTR standard solution (1 mg mL -1 ) and DIQ (0.5 mg mL -1 ) in methanol for TLCdensitometric method. The standard solutions were freshly prepared on the day of analysis and stored in a refrigerator to be used within 24 hr.

TLC-densitometric method:
• Linearity: Aliquots 1-20 µL of MTR standard solution (1 mg mL −1 ) and DIQ (0.5 mg mL -1 ) were applied in the form of bands on a TLC plate. The band length was 4 mm apart from each other and 10 mm from the bottom edge of the plate. Linear ascending development was performed in a chromatographic tank previously saturated with chloroform, toluene, ethanol and acetic acid (9:9:1:1, v/v/v/v) for 1 hr at room temperature. The developed plates were air-dried and scanned at 311 nm using deuterium lamp, absorbance mode at 3 mm×0.45 mm slit dimension and scanning speed of 20 mms −1 . Calibration curves relating the optical density of each spot to the corresponding concentration of MTR and DIQ were constructed. The regression equations were then computed for the studied drugs and used for determination of unknown samples containing them ( Table 2).
Liquid chromatographic method: • Linearity: Portions 0.1-2 mL from MTR standard solution (0.5 mg mL −1 in the mobile phase) and DIQ (0.5 mg mL −1 ) were transferred separately into a series of 10-mL volumetric flasks and completed with mobile phase. The contents of each flask were completed to volume with the mobile phase to get the concentrations of 5-1000 mg mL −1 of MTR and 5-500 mg mL −1 of DIQ. The samples were then chromatographed using the following chromatographic condition. Stationary phase (250 mm×4.6 mm 10 µm) C 18 Lichrosorb TM 10 µm analytical column, Alltech (USA), mobile phase; methanol and acetonitrile, (96:4, v/v). The mobile phase was filtered through a 0.45 µm millipore membrane filter and was degassed for about 15 min in an ultrasonic bath prior to use, flow rate; 0.6 mL min −1 [isocratically at ambient temperature (~25°C)], with UV-detection at 254 nm. The samples were filtered also through a 0.45 µm membrane filter. To reach good equilibrium, the analysis was usually performed after passing ~50-60 mL of the mobile phase, just for conditioning and pre-washing of the stationary phase. The relative peak area ratios (by using 0.04 mg mL -1 MTR and 0.0375 mg mL -1 DIQ as divisor) were then plotted versus the corresponding concentrations of MTR and DIQ to get the calibration graphs and to compute the corresponding regression equations. Concentrations of unknown samples of MTR and DIQ were determined using the obtained regression equations.   Table 3).

Assay of pharmaceutical formulations (Paramibe compound tablets):
Twenty tablets were weighed and grinded to determine the average weight per tablet. Aliquot of the powder tablet equivalent to 250 mg of MTR and DIQ each was extracted by shaking with methanol for 15 minutes then the volume was completed to the mark with methanol to get a concentration of 1 mg mL -1 of MTR and DIQ and proceed as described under each method.

TLC-fractionation
TLC-monitoring of MTR and DIQ was done on thin layer plates of silica gel F254 using chloroform, toluene, ethanol and acetic acid (9:9:1:1, v/v/v/v) as the developing solvent. The developed plates were visualized under short UV-lamp. MTR (R f value=0.13); could be separated from DIQ (R f value=0.741).

TLC-densitometry:
A TLC-densitometric method is described for the determination of MTR in the presence of DIQ without prior separation. Different solvent systems were tried for the separation of MTR and DIQ. Satisfactory results were obtained by using a mobile phase composed of chloroform, toluene, ethanol and acetic acid (9:9:1:1, v/v/v/v), where R f =0.13 and 0.740 for MTR and DIQ, respectively. The separation allows the determination of MTR with no interference from DIQ ( Figure 4). The linearity was confirmed by plotting the measured peak area versus the corresponding concentrations at 311 nm over a range of 1-20 µg spot −1 and 0.5-10 µg spot −1 for MTR and DIQ, respectively where a linear response was obtained (Figures 2 and 3). The regression equation was found to be: A=0.079C+0.092, r=0.9998; where A is the area under the peak and C is the concentration of MTR in µg spot -1 and r is the correlation coefficient and for DIQ, the regression equation was found to be: A 2 =0.438C 2 +0.738, r 2 =0.9999; where A 2 is the area under the peak and C 2 is the concentration of DIQ in µg spot -1 and r 2 is the correlation coefficient ( Table 4).
The precision of the proposed method was checked by the analysis of different concentrations of authentic samples in triplicates. The    High-performance liquid chromatography: A simple isocratic high-performance liquid chromatographic method was developed for the determination of MTR and DIQ in pure form and in pharmaceutical preparation using (250 mm×4.6 mm, 10 µm) C 18 lichrosorb TM analytical column. The mobile phase was consisting of methanol and acetonitrile, (96:4, v/v). The mobile phase was chosen after several trials to reach the optimum stationary/mobile-phase matching. The average retention times under the conditions described are 2.344 min for MTR, 3.548 min for DIQ ( Figure 5). One sample can be chromatographed in less than 6 min. Peak purity was confirmed for the HPLC peaks of both MTR and DIQ by a pilot run using a photodiode array detector. Calibration graph was obtained by plotting the relative peak area ratios (by using 0.04 mg mL -1 MTR and 0.0375 mg mL -1 DIQ as divisor) against concentration of MTR and DIQ (mg mL −1 ). Linearity range was found to be 0.01-1 mg mL −1 for MTR and 0.005-0.5 mg mL −1 of DIQ. The regression equation for MTR: A=39.69C-0.486 (r=0.9999) where A is the relative peak area ratio, C is the concentration of MTR (mg mL −1 ) and r is the correlation coefficient and for DIQ A 2 =38.16C 2 +0.011 (r=0.9999). The mean percentage recovery of pure sample was found to be 99.92 ± 0.433 for MTR and 100.15 ± 0.483 for DIQ (Table 1).

Conclusion
The suggested methods are found to be sensitive and precise. Application of the proposed methods to the analysis of MTR and DIQ in their pharmaceutical formulation shows that excipient do not interfere with the determination. The proposed methods can be used for routine analysis of metronidazole and diiodohydroxyquine in quality control laboratories.